| Antenatal corticosteroid therapy to prevent respiratory distress syndrome. | |
| | |
MedLine Citation:
|
PMID: 7844686 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The recent National Institutes of Health Consensus Development Conference on ANS was strongly supportive of the use of ANS, even for 24 hours but, if possible, for 48 hours, in all fetuses between 24 and 34 weeks of gestation and at risk of preterm delivery regardless of race, gender, or the availability of surfactant replacement. For preterm rupture of membranes at less than 30 to 32 weeks, the use of ANS was also recommended in the absence of amnionitis, and patients eligible for tocolytic therapy were also deemed eligible for ANS. Thus the currently available literature indicates that pediatricians should encourage obstetricians to provide ANS in high-risk pregnancies, as outlined in the proposed National Institutes of Health guidelines. Even if a full 48-hour course of ANS cannot be achieved, ANS given less than 24 hours before delivery is associated with a decreased incidence of intraventricular hemorrhage and periventricular leukomalacia. In addition, we propose that investigators, reviewers, and editors ensure uniformly high maternal ANS exposure, consistent with the realities of clinical practice, when designing, evaluating, and publishing clinical trials with outcomes (e.g., RDS, intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, and death) that can be significantly affected by ANS. Otherwise, studies will continue to be performed on infants who, as fetuses, were deprived of treatment that may have prevented or ameliorated the disorder being assessed. Studies with an infrequent use of ANS may not be applicable or generalizable to an era when the use of ANS is an essential part of perinatal practice. Future trials should document both ANS use and the reasons for failure to achieve an acceptable level of such treatment. |
| | |
Authors:
|
C A Ryan; N N Finer |
Related Documents
:
|
16549266 - Severe obstetric complications and birth characteristics in preterm or term delivery we... 17488376 - Pregnancy after renal transplantation--a five-yr single-center experience. 16940736 - Anencephaly and pregnancy outcome in iran. 17935246 - Association study of protease activated receptor 1 gene polymorphisms and adverse pregn... 3307556 - Altitude-aggravated illness: examples from pregnancy and prenatal life. 15176656 - Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of chil... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Journal of pediatrics Volume: 126 ISSN: 0022-3476 ISO Abbreviation: J. Pediatr. Publication Date: 1995 Feb |
Date Detail:
|
Created Date: 1995-03-08 Completed Date: 1995-03-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375410 Medline TA: J Pediatr Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 317-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pediatrics, University College Cork, Cork Regional Hospital, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use* Controlled Clinical Trials as Topic Female Humans Infant, Newborn Pregnancy Prenatal Care* Respiratory Distress Syndrome, Newborn / prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Short-term use of amoxicillin-clavulanate during upper respiratory tract infection for prevention of...
Next Document: The relationship between drug and alcohol use and peer group associations of college freshmen as the...